drugset
drugset / Trial / NCT05193604

A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

NCT05193604 ↗

Phase 1 Terminated 29 enrolled Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is divided into three phases: single-dose exploration, combination dosage exploration and cohort expansion. The Single-dose exploration stage aims to evaluate the tolerability of TQB2858 injection in subjects with advanced pancreatic carcinoma. The Combination dosage exploration stage aims to evaluate the tolerance of TQB2858 injection combined with chemotherapy in patients with metastatic pancreatic cancer. The cohort expansion phase aims to evaluate the preliminary efficacy of TQB2858 injection combined with gemcitabine, albumin paclitaxel, and with or without anlotinib in patients with metastatic pancreatic cancer，and to explore treatment-related biomarkers.

Timeline

Start
2022-03-24
Primary completion
2023-11-27
Completion
2023-11-27

Outcome

Outcome not reported

Stopped (Business): “Terminated due to the adjustment of sponsor's development strategies and pipeline.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 8 mg Oral
Subject Gemcitabine Small molecule — Intravenous
Subject Paclitaxel Small molecule — Intravenous
Subject TQB2858 Protein / enzyme biologic — Intravenous

Indications

No indication recorded.